ClinicalTrials.gg
RecruitingNCT07665515OVACTUpdated Nov 10, 2026

Study of CryptiVax-1001 in Maintenance Setting for Advanced Serous Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

A Phase 1 interventional study of CryptiVax-1001 in Ovarian Cancer, HGSOC and HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer, sponsored by Epitopea Ltd. Recruiting at 10 sites in United Kingdom. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-10.

Sponsored by Epitopea Ltd · Phase 1, Interventional, and Treatment

How we know

Updated Nov 10, 2026Start date movedSite recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Non-randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 293 studies in Ovarian Neoplasms with a site in United Kingdom — 54 open to participants now, 85 under way, 25 of them phase 3. Ovarian Neoplasms · United Kingdom.

Planned enrollment
195th of 249
50 · median 158
Started
2026
with 10 others
Phase 1
52 of 293
10 open now
Primary completion
2029-03
later than 69 of 84 live
Registered
290th of 293
by date

Among the 293 studies in Ovarian Neoplasms with a site in United Kingdom, this one is the 195th largest by planned enrollment of the 249 interventional ones that give a count, is one of 11 that started in 2026, is one of 52 in phase 1, reaches primary completion later than 69 of the 84 other live ones, and was the 290th registered.

Ovarian Neoplasms

3,390 studies on the registry are indexed under Ovarian Neoplasms; 790 are open to participants now.

Browse Ovarian Neoplasms studies →

Open to participants now

54 of the 293 studies in Ovarian Neoplasms with a site in United Kingdom are open now. Recruiting first, the newest first:

48 more — sign in →

All 54 open studies →

A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →

Who these studies take

Of the 603 Ovarian Neoplasms studies recruiting now, 438 (73%) set no upper age limit and 108 (18%) stop at 75 or younger; 39 take children under 18; 46 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 293 studies in Ovarian Neoplasms with a site in United Kingdom, or all of them as a file.
02

Study summary

Ovarian, fallopian tube, or primary peritoneal cancer, collectively referred to as ovarian cancer, remains the deadliest type of gynaecological cancer. The most common and aggressive form is called high-grade serous ovarian cancer.

The main purpose of this study is to understand whether an experimental study vaccine, CryptiVax-1001, is safe when administered to patients with high-grade serous ovarian cancer (HGSOC). The study vaccine is a cancer vaccine, which aims to delay or possibly prevent the cancer from coming back. However, as this is the first study of the vaccine in patients, the primary purpose of this study is to assess the safety of the study vaccine.

Following surgery and platinum-based chemotherapy participants may enter the trial and receive CryptiVax-1001 as an explorative maintenance therapy.

The main purposes of this study are therefore to:

  • assess how well the study vaccine is tolerated and identify any side effects.
  • analyse the study vaccine's capacity to activate your immune system

The study will test escalating dose levels of CryptiVax-1001 based on the safety evaluations to estimate appropriate future dose levels for CryptiVax-1001.

Read the detailed description

The OVACT study is the First in Human clinical evaluation of Cryptivax-1001 in patients with advanced high-grade serous or predominantly serous ovarian, fallopian tube, or primary peritoneal cancer, following optimal debulking surgery (R0 or R1 after either IDS or PDS), and no recurrence or progression after completion of platinum-based chemotherapy. This phase I/Ib dose escalation and expansion study will assess safety, tolerability, and immunogenicity in a population where there is a high unmet need and no clearly effective maintenance therapy options. By focusing on the BRCAwt/HRP subgroup, the study addresses the majority of patients who currently lack access to biologically-matched maintenance strategies.

The study consist of 2 parts - a dose escalation part and an optional dose expansion part

03

Conditions studied

  • Ovarian Cancer
  • HGSOC
  • HGS Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Browse trials for

Keywords

  • ovarian cancer
  • Maintenance
  • FIGO stage III-IV
  • HRP
  • BRCAwt
  • mRNA vaccine
  • CryptiVax-1001
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to comprehend and are willing to sign the ICF and willing to follow the study procedures
  • Female, aged 18 years of age or older at the time of .
  • confirmed diagnosis of epithelial ovarian, fallopian tube, or primary peritoneal carcinoma of high-grade serous histology or other high-grade predominantly serous subtypes
  • The FIGO 2014 stage III or IV disease at initial diagnosis.
  • Underwent optimal PDS or IDS with residual disease ≤1 cm (R0 or R1 resection)
  • Completed platinum-based chemotherapy (minimum 4 cycles of carboplatin and paclitaxel, or equivalent, received in either or adjuvant, or both settings).
  • In the presence of measurable target lesion, achieved CR or PR per investigator assessment based on 1.1 after completion of chemotherapy. In the absence of measurable target lesion, no new lesion or overt progression per investigator assessment based on RECIST 1.1 after completion of chemotherapy.
  • A minimum of 4 weeks from screening since the last dose of first-line platinum-based chemotherapy but not more than 12 weeks from screening since the last dose of first-line platinum-based chemotherapy.
  • No evidence of radiologic or clinical progression between the end of chemotherapy and baseline screening.
  • Known BRCAwt status.
  • HRP confirmed
  • No prior, current, or planned treatment with bevacizumab or PARPi in the first-line maintenance setting.
  • performance status of 0 or 1.
  • Adequate haematologic and organ function
  • Negative pregnancy test for .
  • HLA type matching Cryptivax-1001

Exclusion criteria

Exclusion Criteria:

  • Non-epithelial or low malignant potential ovarian tumours
  • Presence of uncontrolled ascites or pleural effusion requiring drainage within 4 weeks of screening.
  • Concurrent or history of another malignancy within the past 3 years except for malignancies with a negligible risk of or death
  • Active disease requiring systemic
  • Uncontrolled intercurrent illness that, in the opinion of the investigator, would compromise participant safety or interfere with study assessments
  • History of anaphylactic reaction to mRNA-LNP therapies.
  • Previous treatment with any cancer vaccine, , or adoptive cellular immunotherapy.
  • Administration of any vaccine within 30 days prior to first dosing.
  • Participation in a clinical study involving administration of an IMP (new chemical entity) in the past 90 days or 5 half-lives of that drug (if known) prior to first dosing, whichever is longer.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Dose level 1

    Biological: CryptiVax-1001

  • Experimental
    Dose level 2

    Biological: CryptiVax-1001

  • Experimental
    Dose level 3

    Biological: CryptiVax-1001

  • Experimental
    Dose level 4

    Biological: CryptiVax-1001

  • Experimental
    Dose level 5

    Biological: CryptiVax-1001

  • Experimental
    Recommended Dose

    Recommended phase 2 dose or another safe dose, based on Dose Escalation part

    Biological: CryptiVax-1001

Interventions

  • BiologicalCryptiVax-1001

    i.m injection

06

What researchers measure

Primary outcomes

  1. To evaluate the safety and tolerability of CryptiVax-1001

    Incidence, severity, and relatedness of treatment-emergent adverse events (TEAEs) per Common Terminology Criteria for Adverse Events

    Time frame: Through study completion, an average of up 2 to years

  2. To evaluate the safety and tolerability of CryptiVax-1001

    Incidence and nature of dose-limiting toxicities (DLTs) during the DLT observation period

    Time frame: From Day 1 to Day 21

  3. To evaluate the safety and tolerability of CryptiVax-1001

    Clinically significant changes from baseline in vital signs (body temperature, pulse rate, respiratory rate, systolic and diastolic blood pressure)

    Time frame: Through study completion, an average of up to 2 years

  4. To evaluate the safety and tolerability of CryptiVax-1001

    Clinically significant changes from baseline in clinical laboratory assessments (hematology and chemistry)

    Time frame: Through study completion, and average of up to 2 years

Secondary outcomes

  1. To characterise the immunogenicity of Cryptivax-1001

    Detection and quantification of antigen-specific T cells in peripheral blood at predefined timepoints

    Time frame: At pre-defined timepoints during treatment and Follow-up period, an average of up to 2 years

07

Study locations

10 of 10 sites recruiting
  • Cambridge University Hospitals NHS Foundation Trust - Addenbrookes Hospital
    Cambridge, CB2 0QQ, United Kingdom
    Recruiting
  • The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre
    Edinburgh, EH4 2XR, United Kingdom
    Recruiting
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
    Recruiting
  • St. James's University Hospital
    Leeds, LS9 7TF, United Kingdom
    Recruiting
  • University Hospitals of Leicester NHS Trust -Leicester Royal Infirmary
    Leicester, LE2 7LX, United Kingdom
    Recruiting
  • University College London Hospitals NHS Foundation Trust - Cancer Clinical Trials Unit
    London, NW1 2PG, United Kingdom
    Recruiting
  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital
    London, SE1 9RT, United Kingdom
    Recruiting
  • Royal Marsden NHS Foundation Trust - Royal Marsden Hospital
    London, SW3 6JJ, United Kingdom
    Recruiting
  • Lancashire Teaching Hospitals NHS Foundation Trust - Royal Preston Hospital
    Preston, PR2 9HT, United Kingdom
    Recruiting
  • Royal Marsden NHS Foundation Trust - Institute of Cancer Research
    Sutton, SM2 5PT, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2026 (actual). Primary completion is estimated for Mar 2029, 28 months after the start.

Of 210 industry-sponsored phase 1 interventional studies under Ovarian Neoplasms, half reached primary completion within 47 months of starting (the median), counting those still running; a quarter within 29 and three quarters within 65. This study's planned 28 months is below that.

Counting every sponsor, half of 382 studies reached it within 50 months; a quarter within 32 and three quarters within 76.

Start moved once since we started tracking on Sep 25, 2026: Sep 2026 → Nov 2026, on Nov 10, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2026
First posted
Jun 24, 2026
StartActual
Nov 5, 2026was Sep 2026
Primary completionEst.
Mar 2029
CompletionEst.
Apr 2029
Last update
Nov 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
2 sites changed recruiting status (2 now recruiting)
Show 2 sites
  • The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre · Edinburgh, United KingdomNot yet recruiting→Recruiting
  • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital · London, United KingdomNot yet recruiting→Recruiting
Oct 16, 2026
Start date
Sep 2026→Nov 5, 2026 (actual)
Nov 10, 2026
Show all 2 updates
  1. Nov 10, 2026
    Start date Sep 2026→Nov 5, 2026 (now actual)
    + 1 other change: verification date
  2. Oct 16, 2026
    2 sites changed recruiting status (2 now recruiting)
    Show 2 sites
    • The University of Edinburgh - Western General Hospital - Edinburgh Cancer Research Centre · Edinburgh, United KingdomNot yet recruiting→Recruiting
    • Guy's and St Thomas' NHS Foundation Trust - Guy's Hospital · London, United KingdomNot yet recruiting→Recruiting

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07665515
Lead sponsor
Epitopea Ltd
Responsible party
Sponsor
First posted
Jun 24, 2026
Start date
Nov 5, 2026
Primary completion
Mar 2029 (estimated)
Completion
Apr 2029 (estimated)
Last update
Nov 10, 2026

Study contacts

Head of Development Operations
Contact
Gertrud.Rasmussen@epitopea.com
+4530660105
Head of Oncology Development
Contact
Siri.Torhaug@Epitopea.com
+4795113393
Susana Banerjee, MBBS MA FRCP PhD
principal investigator · Royal Marsden NHS Foundation Trust

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion